for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Eyepoint Pharmaceuticals Inc

EYPT.OQ

Latest Trade

1.38USD

Change

0.00(0.00%)

Volume

235,968

Today's Range

1.35

 - 

1.45

52 Week Range

1.20

 - 

2.82

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
1.38
Open
1.43
Volume
235,968
3M AVG Volume
10.81
Today's High
1.45
Today's Low
1.35
52 Week High
2.82
52 Week Low
1.20
Shares Out (MIL)
108.12
Market Cap (MIL)
149.20
Forward P/E
-2.38
Dividend (Yield %)
--

Next Event

EyePoint Pharmaceuticals Inc Annual Shareholders Meeting

Latest Developments

More

Eyepoint Pharmaceuticals Q3 Loss Per Share $0.15

Eyepoint Pharmaceuticals Reports Second Quarter 2019 Financial Results

EyePoint Pharmaceuticals Says David Price Notified Of His Decision To Resign As CFO, Effective August 9, 2019

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Eyepoint Pharmaceuticals Inc

Eyepoint Pharmaceuticals, Inc., formerly pSivida Corp, develops drug delivery products primarily for the treatment of chronic eye diseases. The Company has developed three products for treatment of back-of-the-eye diseases, which include Medidur for posterior segment uveitis, its lead product candidate that is in pivotal Phase III clinical trials; ILUVIEN for diabetic macular edema (DME), its lead licensed product that is sold in the United States and European Union (EU) countries, and Retisert. Medidur is designed to treat chronic non-infectious uveitis affecting the posterior segment of the eye (posterior segment uveitis). ILUVIEN is an injectable micro-insert that provides treatment of DME from a single injection. Retisert is an implant that provides treatment of posterior segment uveitis. Its product development program is focused on utilizing its two technology platforms, Durasert and Tethadur, to deliver drugs and biologics to treat chronic diseases.

Industry

Biotechnology & Drugs

Contact Info

480 Pleasant St Ste B300

+1.617.9265000

https://eyepointpharma.com/

Executive Leadership

Goran A. Ando

Independent Chairman of the Board

Nancy S. Lurker

President, Chief Executive Officer, Director

Ron I. Honig

Senior Vice President, General Counsel, Secretary

Dario A. Paggiarino

Senior Vice President, Chief Medical Officer

Said Saim

Chief Technology Officer

Key Stats

2.00 mean rating - 4 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2016

0.0K

2017

0.0K

2019(E)

0.0K
EPS (USD)

2016

-0.680

2017

-0.520

2019(E)

-0.577
Price To Earnings (TTM)
--
Price To Sales (TTM)
12.28
Price To Book (MRQ)
4.67
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
163.95
LT Debt To Equity (MRQ)
163.95
Return on Investment (TTM)
-115.54
Return on Equity (TTM)
-92.58

Latest News

Latest News

BRIEF-EyePoint Pharmaceuticals Reports Q3 Loss Per Share $0.15

* EYEPOINT PHARMACEUTICALS REPORTS FISCAL THIRD QUARTER 2018 RESULTS

BRIEF-Eyepoint Pharmaceuticals U.S. Patent And Trademark Office Has Issued Notices Of Allowance For Two Patents Covering DEXYCU

* U.S. PATENT AND TRADEMARK OFFICE HAS ISSUED NOTICES OF ALLOWANCE FOR TWO PATENTS COVERING DEXYCU Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up